Analyst firms · Morgan Stanley · AZN
Morgan Stanley AZN price target and rating history
AstraZeneca PLC (AZN) · Health Care
Morgan Stanley rates AstraZeneca PLC (AZN) Overweight with a $85 price target, as of its latest action on Feb 12, 2025. It has published 4 rating actions on AZN since September 2022, including 1 upgrade and 1 downgrade.
- Current rating
- Overweight
- Price target
- $85
- Median target, all firms
- Too few
- Actions on AZN
- 4
Every Morgan Stanley rating on AZN
- Feb 12, 2025
- Jan 23, 2024
- Apr 11, 2023
- Sep 7, 2022
How other firms rate AZN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Hold | Sep 15, 2026 | |
| RBC Capital Markets | Outperform | Sep 9, 2026 | |
| HSBC | Hold | Jul 13, 2026 | |
| Citigroup | Buy | Jan 27, 2026 |
Questions about Morgan Stanley and AZN
- What is Morgan Stanley's price target for AZN?
- Morgan Stanley's latest stated price target for AstraZeneca PLC (AZN) is $85, from its action on Jan 23, 2024.
- What is Morgan Stanley's rating on AZN?
- Morgan Stanley rates AZN Overweight, a bullish rating, as of Feb 12, 2025.
- When did Morgan Stanley last change its view on AZN?
- On Feb 12, 2025, Morgan Stanley starts coverage at Overweight.
More AZN rating histories
All Morgan Stanley ratingsAZN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.